CRISPR Therapeutics to test highest dose of lipid‑lowering gene editing therapy after mixed durability data

CRISPR Therapeutics presented early‑stage data at the European Society of Cardiology meeting showing that its lipid‑lowering gene editing candidate produced mixed durability results a year after patients were dosed.

The company said it will move forward with testing the highest dose of the therapy in future studies, aiming to improve the durability of the lipid‑lowering effect.

These findings are early and will inform the design of subsequent trials, but they highlight the challenges of achieving consistent long‑term outcomes with gene‑editing approaches.